Shanghai Kechow Pharma, Inc.

Quick facts

Phase 3 pipeline

• Tunlametinib plus Vemurafenib · Oncology
  This combination blocks BRAF and MEK signaling in the MAPK pathway to inhibit growth of BRAF-mutant melanoma and other cancers.

Phase 2 pipeline

• HL-085

Phase 1 pipeline

• HL-003 tablet
• HL-003 tablet Placeco

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Shanghai Kechow Pharma, Inc. portfolio CI brief
• Shanghai Kechow Pharma, Inc. pipeline updates RSS